Breath Based Biomarker Detection & Breath Biopsy - Informing drug development and future treatment regimes By Billy Boyle and Dr Mike Murphy The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes. [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!